Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

 In Italy, hepatitis C virus (HCV) elimination is achievable; nevertheless, limitations stay to attaining the World Health Organization’s elimination targets, and have turn out to be extra pronounced with the unfold of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral remedy for HCV, authorized for 8-week remedy in sufferers with out cirrhosis, and with compensated cirrhosis …

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy Read More »